227 related articles for article (PubMed ID: 11905808)
1. Actin' up: RhoB in cancer and apoptosis.
Prendergast GC
Nat Rev Cancer; 2001 Nov; 1(2):162-8. PubMed ID: 11905808
[TBL] [Abstract][Full Text] [Related]
2. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
[TBL] [Abstract][Full Text] [Related]
3. Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors.
Zeng PY; Rane N; Du W; Chintapalli J; Prendergast GC
Oncogene; 2003 Feb; 22(8):1124-34. PubMed ID: 12606940
[TBL] [Abstract][Full Text] [Related]
4. Farnesyltransferase inhibitors define a role for RhoB in controlling neoplastic pathophysiology.
Prendergast GC
Histol Histopathol; 2001 Jan; 16(1):269-75. PubMed ID: 11193202
[TBL] [Abstract][Full Text] [Related]
5. Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors.
Liu A; Prendergast GC
FEBS Lett; 2000 Sep; 481(3):205-8. PubMed ID: 11007964
[TBL] [Abstract][Full Text] [Related]
6. RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage.
Liu Ax ; Cerniglia GJ; Bernhard EJ; Prendergast GC
Proc Natl Acad Sci U S A; 2001 May; 98(11):6192-7. PubMed ID: 11353846
[TBL] [Abstract][Full Text] [Related]
7. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
[TBL] [Abstract][Full Text] [Related]
8. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.
Du W; Lebowitz PF; Prendergast GC
Mol Cell Biol; 1999 Mar; 19(3):1831-40. PubMed ID: 10022870
[TBL] [Abstract][Full Text] [Related]
9. Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects.
Prendergast GC; Oliff A
Semin Cancer Biol; 2000 Dec; 10(6):443-52. PubMed ID: 11170866
[TBL] [Abstract][Full Text] [Related]
10. Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of the RhoB GTPase.
Wherlock M; Gampel A; Futter C; Mellor H
J Cell Sci; 2004 Jul; 117(Pt 15):3221-31. PubMed ID: 15226397
[TBL] [Abstract][Full Text] [Related]
11. Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter.
Delarue FL; Adnane J; Joshi B; Blaskovich MA; Wang DA; Hawker J; Bizouarn F; Ohkanda J; Zhu K; Hamilton AD; Chellappan S; Sebti SM
Oncogene; 2007 Feb; 26(5):633-40. PubMed ID: 16909123
[TBL] [Abstract][Full Text] [Related]
12. Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells.
Pan J; She M; Xu ZX; Sun L; Yeung SC
Cancer Res; 2005 May; 65(9):3671-81. PubMed ID: 15867362
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical assays of farnesyltransferase inhibition in patient samples.
Adjei AA
Methods Mol Med; 2003; 85():141-5. PubMed ID: 12710205
[No Abstract] [Full Text] [Related]
14. RhoB in cancer suppression.
Huang M; Prendergast GC
Histol Histopathol; 2006 Feb; 21(2):213-8. PubMed ID: 16329046
[TBL] [Abstract][Full Text] [Related]
15. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression.
Zhang B; Prendergast GC; Fenton RG
Cancer Res; 2002 Jan; 62(2):450-8. PubMed ID: 11809695
[TBL] [Abstract][Full Text] [Related]
16. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
[TBL] [Abstract][Full Text] [Related]
17. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
Lebowitz PF; Prendergast GC
Oncogene; 1998 Sep; 17(11 Reviews):1439-45. PubMed ID: 9779989
[TBL] [Abstract][Full Text] [Related]
18. Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoB.
Kamasani U; Liu AX; Prendergast GC
Cancer Biol Ther; 2003; 2(3):273-80. PubMed ID: 12878865
[TBL] [Abstract][Full Text] [Related]
19. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line.
Ghosh PM; Ghosh-Choudhury N; Moyer ML; Mott GE; Thomas CA; Foster BA; Greenberg NM; Kreisberg JI
Oncogene; 1999 Jul; 18(28):4120-30. PubMed ID: 10435593
[TBL] [Abstract][Full Text] [Related]
20. Farnesyltransferase inhibitors in breast cancer therapy.
Dy GK; Adjei AA
Cancer Invest; 2002; 20 Suppl 2():30-7. PubMed ID: 12442347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
